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Abstract: Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs 
are characterized by the negative estrogen and progesterone receptors and negative HER2, 
and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs 
are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and 
metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these 
tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based 
combinations in terms of long-duration response, increased survival, and better quality of life 
of patients with triple-negative metastatic BC. The ongoing trials will give further information 
on the better management of this type of tumor.
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Introduction
Breast cancer (BC) is the most frequent tumor worldwide. In 2008, 1,380,000 new cases 
and 458,000 deaths for BC were reported worldwide, of which there were 332,000 new 
cases and 89,000 deaths in Europe. Although the improvement in early diagnosis and 
adjuvant therapy has reduced mortality, BC is still the main cause of death for cancer 
in women both in industrialized and in developing countries.1
In Italy, BC is the most frequent tumor in women (29%), with about 48,000 new 
cases diagnosed in 2014. In 2011, BC represented the first cause of death for cancer 
in women, with approximately 11,959 deaths estimated. The 5-years relative survival, 
moderately but constantly increasing apart from other comorbidities, is 87% for women 
diagnosed between 2005 and 2007.2
BC is a heterogeneous disease, and therefore, a “golden standard” treatment, 
suitable for all the molecular types of cancer, is not available.3 The most important 
biological markers, not only for classification of BC but also for, the therapeutic 
strategy are the hormonal receptors (estrogen [ER] and progesterone [PgR] receptor) 
and the HER2 receptor status.
The triple-negative BCs (TNBCs)
Tumors that are ER-, PgR-, and HER2-negative are known as TNBC and account for 
about 15% of BCs.4 These tumors develop earlier in life, especially in premenopausal 
women, and have a poorer prognosis than the other types of BC due to the higher 
aggressiveness. These factors may be a major reason for the high-risk relapse, and 
shorter progression-free survival (PFS) and overall survival (OS) reported for this 
disease.3–6
The main general characteristics of TNBC are summarized in Table 1.
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TNBC is not a unique clinical entity. It comprises several 
types of cancers now characterized by molecular profiles, 
which represent different diseases with probably different 
treatment options and different response to chemotherapy, 
biological agents, and/or other therapeutic regimens.
After 2002, gene expression profiles have identified the 
different molecular subtypes of BC, in particular, in the neo-
adjuvant setting7–10 and in particular, regarding TNBC.11 The 
PAM50 gene expression assay12 classifies BCs into at least five 
groups, including luminal A, luminal B, HER2-enriched, basal-
like (BL), and normal breast-like. More recent gene expression 
array analysis has identified six different groups of TNBC, 
including two BLs (BL1 and BL2), an immune-modulatory 
(IM), a mesenchymal (M), a mesenchymal stem-like (MSL), 
and a luminal androgen receptor (LAR) subtype.13 Recently 
Tobin et al reported that with PAM50 intrinsic BC subtypes 
array, 25% of relapses were basal, 32% HER2, 10% luminal 
A, 28% luminal B, and 5% normal breast-like. Importantly, 
the intrinsic subtype at relapse was significantly associated 
with postrelapse survival (P=0.012).14 At the 2015 American 
Society of Clinical Oncology (ASCO) Meeting, Dent et al 
presented interesting data from the Surveillance, Epidemiol-
ogy, and End Results (SEER) database on 10,000 women 
diagnosed in 2010 and 2011 with TNBC in the USA.15 This 
population reflects the current clinical practice in the USA at 
the time: 34% were at stage I, 42% at stage II, 15% at stage III, 
and 6% at stage IV, with a 24-month OS of 97%, 93%, 71%, 
and 27%, respectively. The median OS in metastatic disease 
was 13 months.
The treatment of TNBCs
A proportion of TNBC is highly sensitive to chemotherapy 
but with a short PFS and a lower OS.4–6,13,15 Current therapeutic 
strategies include chemotherapeutic drugs (anthracyclines, 
taxanes, platinum derivatives, and ixabepilone) and bio-
logical drugs.5,6 The efficacy of anthracyclines and taxanes 
in metastatic BC is higher in ER-negative tumors; for this 
reason, both classes are indicated as first-line treatment of 
TNBC, even if with a short-lasting benefit.4 Another group 
of drugs with proven activity in TNBC are the platinum 
derivatives cisplatin and carboplatin.3–6 The biologic drugs 
already evaluated or under active research include angiogen-
esis inhibitors (bevacizumab), PARP1 and EGFR inhibitors, 
tyrosine kinase and ERK inhibitors, mTOR inhibitors, heat 
shock protein 90 inhibitors, and AR antagonists.3–6,13
Guidelines for the treatment of TNBCs
There are no specific guidelines for the management of 
TNBC: the National Comprehensive Cancer Network 
(NCCN), European Society for Medical Oncology (ESMO), 
and Associazione Italiana di Oncologia Medica (AIOM) 
Guidelines recommend that TNBC be treated with chemo-
therapy (monotherapy or combination therapy) but do not 
specify the most appropriate drugs (Table 2).1
The ESMO Guidelines states that cytotoxic chemo-
therapy is the standard of care for the treatment of TNBC 
and that the choice of the regimen should be made after 
consideration of disease-related factors (disease-free 
survival [DFS], previous therapies and response, tumor 
burden, and need for rapid disease/symptom control) and 
patient-related factors (patient preferences, biological age, 
menopausal status, comorbidities and performance status, 
and socioeconomic and psychological factors). Combination 
chemotherapy is more often required because of frequent 
visceral involvement, aggressive course, and risk of rapid 
patient deterioration. Finally, there is no a standard approach 
for chemotherapy after first line.1
The role of taxanes in TNBC
The role of taxanes in TNBC is well established after 
the many studies evaluating the efficacy of taxane-based 
regimens in neoadjuvant, adjuvant, and metastatic disease 
settings.
The neoadjuvant setting
Neoadjuvant therapy has been used for a long time for reduc-
ing the size and the extension of locally advanced tumors, 
but now it is extensively used also in early BC not suitable 
for primary conservative surgery, with an added predictive 
value for the long-term outcome of the disease. Actually the 
best efficacy target for neoadjuvant therapy is expressed as 
pathological complete response (pCR). The predictive value 
Table 1 General characteristics of triple-negative BC4,5
•	 weak association between tumor size and lymph node involvement
•	 Quick growth and tissular density similar to normal tissue
•	 High expression of BRCA1 mutation
•	 High risk of early relapse
•	 Peak recurrence between the first and third years after diagnosis
•	 Metastases are rarely preceded by local recurrence
•	 Higher incidence in younger women, Afro American or Hispanic,  
and in low socioeconomic conditions
•	 Stronger association with obesity
•	 Higher incidence of brain metastases
•	 Most deaths occur in the first 5 years
•	 Rapid progression from the onset of metastasis to death
Abbreviation: BC, breast cancer.
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of pCR as a surrogate for long-term clinical benefit has been 
recently confirmed by the retrospective pooled analysis of 
Cortazar et al.18 This meta-analysis was based on the pCR, 
overall response rate (ORR), and event-free survival (EFS) 
data of 12 international clinical trials on a total 11,550 
patients. The analysis compared the three main definitions 
of pCR in order to establish their association with long-term 
efficacy: ypT0 ypN0 (no invasive and in situ tumor in the 
breast and auxiliary lymph nodes); ypT0/is ypN0 (no invasive 
tumor in the breast and auxiliary lymph nodes, independent 
of the presence of in situ ductal carcinoma); and ypT0/is 
ypN0/is (no invasive tumor in the breast, independent of the 
presence of in situ ductal carcinoma or lymph nodes involve-
ment). The retrospective analysis showed that complete 
tumor eradication (breast and lymph nodes) (ypT0 ypN0 or 
ypT0/is ypN0 pCR) was strongly associated to the improve-
ment of EFS and OS as compared with tumor eradication in 
the breast only (ypN0/is). The better combination between 
pCR and long-term effect was observed in patients with an 
aggressive tumor (TNBC; high-grade; ER/PgR-positive, 
HER2-negative; HER2-positive; and ER- and PgR-negative). 
Authors also stated in the paper that “pooled analysis could 
not validate pCR as a surrogate end point for improved EFS 
and OS” and that the potential explanation could be the het-
erogeneous BC subtypes in the examined trials.19
These results were confirmed by a further analysis of 
pooled data showing that the association between pCR and 
long-term outcome is particularly evident in patients with 
aggressive BCs.20,21
Several studies on neoadjuvant therapy confirmed the sen-
sitivity of TNBC to cytotoxic drugs, as well as the importance 
of taxane-based chemotherapy. Rouzier et al22 evaluated the 
molecular-based chemosensitivity in 82 patients treated with 
anthracyclines and taxanes neoadjuvant therapy, and a pCR 
was observed in 45% of BL tumors and in 6% of luminal 
tumors (A and B).
An MD Anderson Cancer Center study23 evaluated 1,118 
patients (23% with TNBC) treated with neoadjuvant therapy. 
The pCR rates were significantly higher in TNBC treated with 
anthracyclines-based regimens. Anthracycline- and taxane-
based regimens were more active, but both PFS and 3-year 
OS were significantly worse in TNBC (hazard ratio [HR] 
1.86, 95% confidence interval [CI] 1.39–2.50, P,0.0001; 
and HR 2.53, 95% CI 1.77–3.57, P,0.0001, respectively). 
Patients with TNBC with residual disease had a poorer out-
come that did those with non-TNBC tumors (3-year DFS rate 
68% vs 88%) (P=0.0001). In patients with pCR, both PFS 
and OS were no different between TNBC and other types of 
tumors (Figure 1).
Table 2 Taxanes and their combinations recommended by NCCN, eSMO, and AiOM guidelines for triple-negative BC1,16,17
NCCN16 ESMO1 AIOM17
Monotherapy
Paclitaxel
Docetaxel
Nab-paclitaxel
Monotherapy (without extensive visceral  
involvement/symptomatic)
weekly paclitaxel
weekly docetaxel or q3w
Nab-paclitaxel
Monotherapy
Paclitaxel
Docetaxel
Nab-paclitaxel
Combinations
Docetaxel + capecitabine
Gemcitabine + paclitaxel
Paclitaxel + bevacizumab
Combinations (with extensive visceral  
involvement/symptomatic)
Anthracycline + taxane (paclitaxel or docetaxel)
Docetaxel + capecitabine
Paclitaxel + gemcitabine
Paclitaxel + vinorelbine
Paclitaxel + carboplatin
Combinations
Anthracycline + taxane  
(paclitaxel or docetaxel)
Docetaxel + capecitabine
Paclitaxel + gemcitabine
Docetaxel + gemcitabine
Paclitaxel + bevacizumab
Abbreviations: AiOM, Associazione italiana di Oncologia Medica; eSMO, european Society for Medical Oncology; NCCN, National Comprehensive Cancer Network; 
q3w, every 3 weeks; BC, breast cancer.
Figure 1 effect of neoadjuvant chemotherapy in data of triple-negative BCs vs non-
triple-negative BCs.23
Notes: aP=0.034; bP=0.0001; cP=0.007.
Abbreviations: Anthra, anthracycline; OS, overall survival; Other, non-triple-
negative tumors; pCR, pathological complete response; PFS, progression-free 
survival.
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A similar study24 carried out in the same center on 1,731 
patients treated with neoadjuvant anthracycline and taxane 
regimens reported an overall pCR rate of 13%. In the 317 
TNBC patients, the pCR rate was 22.4%. In this group, pCR 
seemed to be a strong predictive factor of long-term survival, 
with 84% of patients still alive at 10 years vs 59% in the case 
of residual disease.
In a retrospective Japanese study, among 151 patients 
treated with anthracycline- and taxane-based neoadjuvant 
therapy, TNBC (14%) had a pCR rate higher than did the 
non-TNBC tumors (38% vs 12%).25
A study by the Istituto Europeo di Oncologia26 in 30 
patients with TNBC, four cycles of epirubicin, cisplatin, and 
continuous-infusion fluorouracil followed by three cycles 
of weekly paclitaxel achieved an objective response in 26 
cases (86%) and a pCR in 12 cases (40%). A total 26 patients 
(86%) underwent conservative surgery, and the 2-year DFS 
was 87.5%.
The GeparDuo27,28 study evaluated the pCR rate in 913 
women randomized to neoadjuvant doxorubicin and doc-
etaxel for four cycles or doxorubicin and cyclophosphamide 
(AC) for four cycles followed by docetaxel for four cycles. 
The overall pCR rate was 10.6% (7% with the two-drug regi-
men and 14.3% with the triplet one). It should be noted that 
GeparDuo also tested four vs eight cycles of chemotherapy. 
Either way, the probability of pCR was three times higher 
in the endocrine receptor-negative tumors vs the endocrine 
receptor-positive subgroup (22.8% vs 6.2%). The trial 
I-SPY29 evaluated 190 patients treated with neoadjuvant 
anthracyclines and taxanes: in the subgroup of TNBCs (28%), 
the pCR rate was 33%, significantly higher than that observed 
in HER2-negative and ER/PgR-positive tumors (10%).
The efficacy of taxane-based neoadjuvant therapy was 
further confirmed by more recent trials. Wu et al30 evalu-
ated the efficacy of neoadjuvant therapy with docetaxel plus 
epirubicin, and the OS in 54 patients with TNBC and in 195 
patients with non-TNBC. A pCR was observed in 25.9% 
of TNBCs, significantly higher than in the other subtypes 
(P=0.019). However, patients with TNBC with residual 
disease had a shorter 5-year DFS and OS vs patients with non-
TNBC. In the subgroup with pCR, survival was equivalent 
between the two groups, similarly to data previously reported 
by the MD Anderson group.23
Sakuma et al31 evaluated 44 patients with TNBC treated 
with anthracycline- and taxane-based neoadjuvant therapy, 
and reported a pCR in 36% of cases with a long-term outcome 
significantly better that that with residual disease.
The use of angiogenesis inhibitors in TNBC is supported 
by the highly proliferative nature of this tumor and by the 
importance of VEGF for its microvascular growth,32 and 
bevacizumab could play a role in the neoadjuvant setting.33 
The recent Phase II KCSG BR-0905 trial34 evaluated the 
addition of bevacizumab to neoadjuvant docetaxel and carbo-
platin in 45 patients with TNBC. Also, in this study, the pCR 
rate was high (42%), with a clinical response rate of 96%. 
This allowed a conservative surgery in 35 cases (78%). The 
Phase III GeparQuinto trial35 compared epirubicin and cyclo-
phosphamide followed by docetaxel with or without bevaci-
zumab in 1,948 HER2-negative BC patients, with an overall 
pCR rate (breast and nodes) of 18.4% with bevacizumab vs 
19.9% for controls (P=0.04). Among the 663 patients with 
TNBC, pCR rates were 39.3% with bevacizumab vs 27.9% in 
controls, and the difference was highly significant (odds ratio 
[OR] 1.67, 95% CI 1.21–2.31, P=0.003). Results in the ER/
PgR-positive population were not as good, with or without 
bevacizumab, with a pCR rate of 7.8% and 7.7%, respectively 
(OR 0.99, 95% CI 0.66–1.50, P=1.00). It should be noted that 
the test for interaction showed just a trend to significance.
The New England Journal of Medicine published a report 
by Bear et al36 of another trial of neoadjuvant chemotherapy 
with or without bevacizumab, the NSABP B-40 study. This 
Phase III randomized trial assigned 1,206 patients with 
HER2-negative BC to receive docetaxel (100 mg/m2 every 
21 days) or docetaxel (75 mg/m2 day 1) plus capecitabine 
(825 mg/m2 twice a day days 1 to 14) or docetaxel (75 mg/m2 
day 1) plus gemcitabine (1,000 mg/m2 days 1 and 8) for 
four cycles. All regimens were followed by AC for a further 
four cycles. All patients were also randomized to receive 
bevacizumab (15 mg/kg) or not for the first six cycles of 
chemotherapy. Results showed first of all that the addition of 
capecitabine and gemcitabine did not improve the rate of pCR 
vs docetaxel alone and showed increased toxicity and that the 
toxicity of bevacizumab was manageable and as expected 
from previous trials and, significantly increased the overall 
pCR rate (34.5% vs 28.2%) (P=0.02). The multiple logistic 
regression model showed that TNBC subtype, high grade, 
and smaller tumor size were associated with higher rates of 
pCR in the breast, but when considering the pCR in breast and 
nodes, the addition of bevacizumab was significantly related 
to a better result in hormone receptor-positive tumors only.
In the randomized Phase II GeparSixto trial,37 315 patients 
with TNBC were treated with weekly paclitaxel plus nonpegy-
lated liposomal doxorubicin (once a week for 18 weeks) and 
bevacizumab every 3 weeks and were randomized to receive 
weekly carboplatin (area under the time–concentration curve 
[AUC] =2) or not. The pCR (ypT0ypN0) rate was 16% 
higher with the addition of carboplatin (53.2% vs 36.9%) 
(P=0.005). The toxicity was also significantly higher, with 
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53% discontinuation (41% with AUC reduced to 1.5). Data 
on the BRCA mutation are not yet available in order to assess 
the correct role of carboplatin.
At the ASCO 2015 meeting, further interesting data from 
the GeparSixto trial were presented,38 showing that the addi-
tion of carboplatin to taxane and anthracycline increased the 
pCR rate from 45.2% to 64.9% in TNBC with homologous 
recombination deficiency. In tumors without deficiency, 
carboplatin did not improve the pCR rate.
Other data on the role of bevacizumab added to neoadju-
vant chemotherapy were also recently reported from the Can-
cer and Leukemia Group B (CALGB) 40603 trial.39 A standard 
chemotherapy plus carboplatin and bevacizumab obtained 
a pCR rate higher (60%) vs the same without bevacizumab 
(49%) or standard chemo alone (+/- bevacizumab: 43% vs 
39%). The addition of carboplatin led to significant but small 
improvement in pCR rate, at the price of increased toxicity. At 
the ASCO 2015 meeting, an update of this trial reported a rate 
of conversion to the possibility of breast conservative surgery 
in favor of the bevacizumab arm of 42% in TNBC.40
In June 2015, Earl et al41 reported results of the multicenter 
British ARTemis Phase III trial. Between 2009 and 2013, 880 
patients with HER2-negative early BC (tumor size .20 mm, 
clinically positive or negative Nodes) were randomized to 
three cycles of docetaxel (100 mg/m2 every 21 days) followed 
by three cycles of 5-Fluoruracile, Epirubicine at 100 mg/sqm, 
Cyclophosphamide regimen every 21 days, with or without 
four cycles of bevacizumab (15 mg/kg). The primary end 
point was pCR (tumor and nodes). Results showed a sig-
nificant increase of pCR with the addition of bevacizumab 
(22% vs 17%) (P=0.03). The most important result of this 
trial is the great added value of bevacizumab in the TNBC 
population (pCR 45% vs 31%) (P,0.0001) as compared 
with the ER-positive HER2-neg population (pCR 7% vs 6%). 
ARTemis results are consistent with those of GeparQuinto35 
and CALGB 4060339 and could also explain the different 
results for the HER2-negative ER-positive population in 
the NSABP B40 trial,36 where the cutoff for the ER-positive 
population was very low (1% of positive cells) compared with 
both GeparQuinto and CALGB 40603 (cutoff 10%).
The role of pCR as a surrogate end point for DFS and OS 
has so far not been defined, and the answer will be possible 
from an extensive meta-analysis of long-term results of the 
Phase III randomized trials.
The adjuvant setting
Studies in adjuvant setting also confirmed the activity and 
relevance of taxanes in TNBCs. Hayes et al retrospectively 
analyzed the histological samples of 1,322 patients enrolled 
in the CALGB 9344 study42 in order to evaluate the role of 
HER2 status on clinical end points. Patients were divided 
in four groups: endocrine receptor- and HER2-negative 
(TNBC); endocrine receptor- and HER2-positive; endo-
crine receptor-positive and HER2-negative; endocrine 
receptor-negative and HER2-positive. Adding paclitaxel to 
anthracycline improved DFS both in HER2-positive patients, 
independently from endocrine receptor status, and in TNBC 
patients. No clinical benefit was observed in HER2-negative 
and endocrine receptor-positive tumors. This explorative 
analysis suggests that paclitaxel added to the adjuvant regi-
men significantly improves the outcome in TNBCs.
The study of Sparano et al43 conducted on 4,950 patients, 
evaluated in the adjuvant setting the efficacy of AC followed 
by weekly or 3-weekly (q3w) docetaxel or paclitaxel. The 
results showed an improvement both in DFS and 5-year 
OS with weekly paclitaxel with respect to q3w paclitaxel. 
In TNBCs, the benefit of conventional weekly paclitaxel in 
term of DFS was 37% higher than the q3w regimen.
Other studies also evaluated anthracycline- and taxane-
based adjuvant therapy in TNBC. The Breast Cancer Inter-
national Research Group (BCIRG) 001 study44 compared 
docetaxel plus doxorubicin plus cyclophosphamide vs fluo-
rouracil plus doxorubicin plus cyclophosphamide, showing 
that taxane was able to increase the efficacy in the TNBC 
cohort. Similar results were reported in a multicenter random-
ized Phase III study by Loesch et al45 comparing AC followed 
by paclitaxel with doxorubicin and paclitaxel followed by 
weekly paclitaxel in high-risk BC patients.
Finally, a recent meta-analysis of 14 randomized Phase III 
studies on 25,067 patients46 evaluated the impact of a 
docetaxel-based adjuvant therapy on DFS and OS in early 
BC. The improvement in survival obtained with docetaxel-
based regimens with respect to docetaxel-free regimens was 
observed, not only in the general population but also, in 
several subgroups, TNBC included.
All the above cited data confirm the high activity of 
taxanes in TNBC; however, at the ASCO 2015 meeting, 
interesting data from the adjuvant Phase III TITAN trial 
were reported.47 In this trial, 614 early TNBC patients were 
randomized to adjuvant AC for four cycles followed by 
ixabepilone q3w for four cycles or weekly paclitaxel for 
12 cycles. At a median follow up of 48 months, no difference 
was found between the two arms in 5-year DFS (87% vs 
85.4%) or OS (92.3% vs 90.2%). Both regimens performed 
well, with different toxicity profile: ixabepilone had lower 
rate of neurotoxicity and fewer dose reductions.
The open-label, randomized Phase III BEATRICE study 
assessed the addition of bevacizumab to chemotherapy in 
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the adjuvant setting for 2,591 women with TNBC. The 
primary analysis showed that invasive DFS (IDFS) events 
were observed in 16% of patients treated with chemotherapy 
alone compared with 14% of those treated with chemotherapy 
plus bevacizumab (P=0.18); the 3-year IDFS was 82.7% and 
83.7%, respectively. After 200 deaths, no difference in OS 
was noted between the groups (P=0.23). The addition of 
bevacizumab was associated with increased incidences of 
Grade 3 or worse hypertension, severe cardiac events, and 
treatment discontinuation. For these reasons, the authors 
stated that bevacizumab cannot be recommended as adjuvant 
treatment in unselected patients with TNBC.48
The metastatic setting
Conventional taxanes have a central role in the treatment of 
metastatic BC, based on several evidences of their benefits 
on clinical outcomes, such as OS, time to progression (TTP), 
and ORR.49
Even if conventional taxanes demonstrated to be more 
active in endocrine receptor-negative tumors and are indi-
cated in the first-line treatment of TNBC (although a specific 
benefit in this setting was not observed), it should be consid-
ered that they are commonly used in adjuvant therapy and 
cannot be rechallenged in case of short disease-free interval 
(,12 months).4,50
The duration of response to chemotherapy of TNBC is 
usually short, as demonstrated by a retrospective analysis of 
111 cases treated with monotherapy or combinations.51 The 
mean duration of the response was 12 weeks after first-line 
treatment, 9 weeks after second-line, and 4 weeks after third-
line treatment. For this reason, some recent studies evaluated 
new first-line therapeutic regimens, combining taxanes with 
other cytotoxic drugs or new molecules.
The role of bevacizumab in metastatic disease was also 
explored in several Phase III trials. A meta-analysis of the 
three main Phase III studies of bevacizumab combined 
with first-line chemotherapy, showed an increase of PFS 
vs chemotherapy alone (8.1 vs 5.4 months) in 621 patients 
with TNBC.52 In the RIBBON-2 study,53 patients progressed 
after first-line chemotherapy and treated with second-line 
bevacizumab with or without chemotherapy were enrolled. 
Recently, a subanalysis of 159 (23%) cases of TNBCs in 
the RIBBON-2 study, most treated with taxanes, reported 
a median PFS of 6 months with bevacizumab plus chemo-
therapy vs 2.7 months with chemotherapy alone (P=0.0006); 
the median OS was 17.9 vs 12.6 months (P=0.0534), and 
the ORR was 41% vs 18% (P=0.0078). The Phase III 
IMELDA Trial was published by Gligorov et al 54 in late 
2014, mainly based on the meta-analysis of Gennari et al55 
which found a first-line chemotherapy until progression led 
to a longer PFS and a small but appreciable increase in OS.55 
In the AVADO52 trial where the response rate was very 
high, but a prolonged treatment with docetaxel was 
unrealistic because of cumulative toxicity. The open-
label Phase III IMELDA trial investigated the combina-
tion of capecitabine and bevacizumab after initiation 
of docetaxel and bevacizumab. Previously untreated 
HER2-negative metastatic BC patients were treated 
with three to six cycles of bevacizumab (15 mg/kg) 
and docetaxel (75–100 mg/m2) every 21 days. Patients with 
progressive disease were excluded, and responders (com-
plete or partial response [CR or PR]) or patients with stable 
disease were randomized to maintenance with bevacizumab 
or bevacizumab plus capecitabine (1,000 mg/m2 twice daily 
days 1–14 q3w, until disease progression (PD), unacceptable 
toxicity, or consent withdrawal. Bevacizumab and capecit-
abine significantly improved overall median PFS (11.9 vs 4.3 
months) (HR 0.38, P,0.001) and OS (39 vs 23.7 months) 
(HR 0.43, P,0.001), without unexpected safety problems. 
In the TNBC population, the median PFS was 7.6 months 
with the combination and 3.6 months with bevacizumab 
alone (HR 0.48). At the 2014 San Antonio Symposium, the 
OS in prespecified subgroups was presented, confirming 
the very good result in the TNBC population, with a death 
risk reduction of 53% (HR 0.47) compared with 57% in the 
overall population and with a 2-years OS of 62%.54
Fan et al56 evaluated the efficacy of docetaxel combined 
with cisplatin or capecitabine in the first-line treatment of 
patients with metastatic TNBC. The ORR was significantly 
higher in patients treated with docetaxel plus cisplatin than 
with docetaxel plus capecitabine (63% vs 15.4%) (P=0.001), 
as were the median PFS (10.9 vs 4.8 months) (P,0.001) and 
median OS (32.8 vs 21.5 months) (P=0.027), confirming the 
role of platinum in TNBC.
At the 2014 San Antonio Symposium, Tutt et al57 pre-
sented results from the randomized Phase III TNT trial com-
paring carboplatin (AUC =6) with docetaxel (100 mg/m2), 
both every 21 days for six cycles, as first-line treatment in 
376 patients with advanced TNBC or BRCA1/2-positive 
BC. The primary end point was the objective response rate 
in the intent-to-treat population. Of note, nearly all cancers 
with BRCA1 mutations are triple negative, whereas tumors 
with BRCA2 mutations can be either ER positive or triple 
negative. So, in the BRCA2 population of this study, there 
were also some ER-positive patients.
The TNT trial was based on the hypothesis that because 
BRCA1/2 germline mutations produce BCs that have defects 
in homologous recombination DNA repair, carboplatin would 
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be lethal to cells with germline and somatic mutations in 
BRCA1/2. In other words, carboplatin might be an especially 
good therapy in terms of exploiting the defect in homologous 
recombination DNA repair, and this is why patients with 
BRCA1/2 mutations were included with TNBC patients. The 
results showed no significant difference in response rates 
between carboplatin and docetaxel in the overall patient 
group or in patients who received either agent as first-line 
therapy and then crossed over to the other agent as second-
line treatment.
The only significant difference was in patients with 
BRCA1/2 germline mutations (response rate with carboplatin 
68% vs 33% with docetaxel) (P=0.03). Similarly, PFS was 
6.8 months vs 4.5. This is the outstanding result of this study, 
showing that platinum compounds could be more active 
than taxanes in patients with BRCA1/2 germline mutations. 
In patients with wild-type BRCA1/2, there was a nonsig-
nificant trend for a higher response rate with docetaxel. 
No difference was found in PFS or OS.
A Japanese study,58 interesting despite the low number 
of patients, evaluated the efficacy of the combination gem-
citabine plus paclitaxel in 56 patients with metastatic BC, 
including 14 cases of TNBC. In the general population, the 
ORR was 44.6%, median TTP was 8.6 months, and median 
OS was 27.1 months, whereas in the TNBC population, the 
ORR was 35.7% and median TTP was 6 months.
An interesting recent Phase I study59 evaluated the 
efficacy and safety of olaparib, an oral PARP inhibitor, 
associated to paclitaxel in first- or second-line treatment in 
19 patients with TNBC. Despite a good global efficacy (37% 
of confirmed partial responses), the combination of olaparib 
plus weekly paclitaxel had an unexpected higher neutropenia 
rate, even after secondary prophylaxis.
Approximately 10% to 15% of TNBC express androgen 
receptor (AR).13 The LAR subtype of TNBC actually is 
a Luminal one, rich in AR,13 and this is the rationale for 
an antiandrogen therapy. Enzalutamide is a potent AR 
inhibitor, but AR expression does not necessarily mean 
sensitivity to endocrine treatment. At the ASCO 2015 
meeting, Parker et al60 reported results of a randomized 
study in which a new gene profile was able to predict the 
benefit from treatment with enzalutamide in metastatic 
TNBC. Actually, 50% of patients with the positive 
diagnostic profile obtained 39% of clinical benefit rates 
at 16 months and 36% at 24 months, versus 11% and 6% 
respectively of patients with the negative diagnostic profile. 
This interesting result may be useful for a more targeted 
selection of TNBC patients suitable for an antiandrogen 
treatment in future trials.
In conclusion, the main reason of failure in metastatic 
BC is resistance to the standard drugs, which can be intrinsic 
or acquired. Patients with disease progression or resistance 
could not have a cross-resistance with other drugs, such as 
capecitabine, gemcitabine, vinorelbine, eribulin, or nab-
paclitaxel, which demonstrated their efficacy in patients 
with advanced BC pretreated with anthracyclines and/or 
taxanes.32
Nab-paclitaxel
Nab-paclitaxel is a nanoparticle with median size 130 nm, 
solvent-free.61,62 Nanotechnology utilizes the natural proper-
ties of albumin to potentiate the selective uptake of paclitaxel 
in tumors and for targeting the drug directly into the cancer 
cells. Preclinical studies showed that nab-paclitaxel achieves 
a 33% higher tumor uptake vs conventional paclitaxel but 
lower uptake in normal tissue and plasma; furthermore, these 
studies demonstrated a lower toxicity in animals, a higher 
activity in animal models with xenograft tumors (breast, 
lung, ovarian, prostate, and colon), and that nab-paclitaxel 
is four times more efficient in crossing layers of endothelial 
cells.63–65
This unique and innovative mechanism of transport of 
nab-paclitaxel allows a higher concentration of the active 
drug in the tumor, better efficacy, and safety vs those for both 
conventional paclitaxel and docetaxel observed in clinical 
trials in metastatic BC.
Nab-paclitaxel in the metastatic setting
The Phase III pivotal study by Gradishar et al66 evaluated the 
efficacy of nab-paclitaxel (260 mg/m2 intravenously [IV] q3w 
without premedication) vs conventional paclitaxel (175 mg/m2 
IV with premedication) in 454 patients with metastatic BC. 
Nab-paclitaxel resulted significantly superior in ORR (33% 
vs 19%) (P=0.001) and in TTP (23 vs 16.9 weeks) (P=0.006) 
vs conventional paclitaxel; OS was significantly higher in 
patients treated with nab-paclitaxel beyond the first line than 
in patients treated with conventional paclitaxel (56.4 vs 46.7 
weeks) (P=0.024). As far as safety is concerned, the grade 3/4 
neutropenia rate was significantly lower with nab-paclitaxel 
(34% vs 54%) (P,0.001), and Grade 4 neutropenia alone 
was even better (9% vs 22%) (P,0.001), despite an almost 
double dose of paclitaxel (49% higher); the grade 3 sensi-
tive neuropathy rate was higher (10% vs 2%) (P,0.001) 
but rapidly reversed to a #2 grade than did conventional 
paclitaxel. This study shows an important benefit of q3w 
nab-paclitaxel over q3w conventional paclitaxel, with an 
improved therapeutic index and the lack of premedication 
with steroids.
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About the optimal schedule of conventional 
paclitaxel
It is widely accepted that weekly paclitaxel is a “different 
treatment” compared with the q3w schedule, in any setting.67 
In the neoadjuvant setting, the weekly schedule was superior, 
with a 28.2% pCR vs 15.7% (P=0.02);68 in the adjuvant setting, 
by the already cited trial of Sparano et al,43 the comparison of 
weekly to q3w paclitaxel (and docetaxel) after four cycles of 
AC showed a significant advantage in DFS in favor of weekly 
paclitaxel (HR 1.27, P=0.006), in particular in TNBC. In the 
metastatic setting, weekly paclitaxel was also significantly 
superior to the q3w schedule69 in response rate (42% vs 29%) 
(OR 1.75, P=0.0004), median TTP (9 vs 5 months) (HR 1.43, 
P,0.0001), and median OS (24 vs 12 months) (HR 1.28, 
P=0.0092), at an expected price of a significant increase in 
Grade 3 neurotoxicity (824% vs 12%) (P=0.0003), which was 
defined as the treatment-limiting toxicity.
Nowadays the q3w conventional paclitaxel schedule is 
rarely used, and the preferred schedules for conventional 
taxanes are weekly paclitaxel or q3w docetaxel.
An open-label, multicenter, randomized Phase II study70 
evaluated the efficacy and safety of three nab-paclitaxel-
based regimens (300 mg/m2 q3w, 100 mg/m2 weekly, or 
150 mg/m2 weekly) vs docetaxel 100 mg/m2 q3w in the 
first-line treatment of 302 patients with metastatic BC. The 
nab-paclitaxel 150 mg/m2 weekly schedule obtained signifi-
cantly longer PFS than did docetaxel by both independent 
(12.9 vs 7.5 months) (P=0.0065) and investigator (14.6 
vs 7.8 months) (P=0.012) assessment. According to the 
independent radiologist review, both schedules of 150 mg/
m2 (49%) and 100 mg/m2 (45%) weekly of nab-paclitaxel 
demonstrated a higher ORR vs docetaxel (35%), but this 
did not reach statistical significance. The evaluation of ORR 
by investigators showed a statistically significant differ-
ence between the weekly schedules of nab-paclitaxel and 
docetaxel (74% with 150 mg/m2 and 62% with 100 mg/m2 
vs 39%) (P,0.05). The final analysis of OS of this study, 
published by Gradishar et al in 2012,71 showed a median 
OS of 33.8 months with weekly nab-paclitaxel 150 mg/m2 
vs 22.2, 27.7, and 26.6 months, respectively, with weekly 
nab-paclitaxel 100 mg/m2 and 300 mg/m2 q3w, and docetaxel 
100 mg/m2 q3w (P=0.047).
A trend toward a longer OS was noted in all the patients 
subgroups, independent from age (,65 vs $65 years), 
type of metastatic site (visceral vs not), number of visceral 
lesions (,5 vs $5), and menopausal status. The best clinical 
response was already observed after two cycles of treatment 
with weekly nab-paclitaxel 150 or 100 mg/m2 vs five cycles 
of docetaxel (P,0.001), highlighting the quick response 
of this new drug. Further, the median number of cycles 
administrated with weekly nab-paclitaxel 150 mg/m2 was 
higher than with docetaxel (eight vs ten). The weekly dose 
of 150 mg/m2 of nab-paclitaxel could be the most effective 
dosage, from a clinical point of view, for previously untreated 
and fit patients.71
A retrospective analysis of previous studies (CA012 
and CA024)72 evaluated the efficacy of nab-paclitaxel in 
patients with poor prognostic factors: dominant visceral 
metastasis and short DFS. In the first study (CA012), the 
ORR was higher in patients treated with nab-paclitaxel vs 
those treated with conventional paclitaxel both in domi-
nant visceral metastasis (42% vs 23%) (P=0.022) and in 
short DFS (43% vs 33%) (P=0.417). Also, in the second 
study (CA024), patients treated with weekly nab-paclitaxel 
showed a better ORR than did patients treated with doc-
etaxel, significantly higher in the cases of dominant visceral 
metastases.
PFS and OS showed a similar trend, but a statistically 
significant difference was observed only in the second 
study, which showed PFS in dominant visceral metastasis 
(13.1 months for nab-paclitaxel 150 mg/m2 vs 7.8 months 
for docetaxel [P=0.019] and 7.5 months for nab-paclitaxel 
100 mg/m2 [P=0.010]). The results of this analysis suggest 
that nab-paclitaxel is a therapeutic option also for patients 
with very aggressive disease.
The study of Blum et al73 demonstrated the efficacy of 
monotherapy with weekly nab-paclitaxel at 100 mg/m2 (n=106) 
or 125 mg/m2 (n=75) in patients with metastatic BC heavily pre-
treated with conventional taxanes. The ORR was 14% and 16% 
with 100 mg/m2 and 125 mg/m2, respectively; stable disease for 
more than 16 weeks was observed in 12% and in 21% of cases, 
respectively. Median PFS and OS were 3 and 9.2 months with 
100 mg/m2, and 3.5 and 9.1 months with 125 mg/m2.
Nab-paclitaxel, administered to patients with metastatic 
BC pretreated with conventional taxanes, has a significant 
antitumor activity and is well tolerated. Further evidence of 
efficacy of nab-paclitaxel in patients previously treated with 
conventional taxanes is the recently published prospective, 
multicenter Italian study that aimed to evaluate the efficacy 
and safety of nab-paclitaxel 260 mg/m2 q3w in second-line 
treatment of 52 HER2-negative, taxane-pretreated meta-
static BC patients. The ORR was 48% (13.5% of complete 
response), the overall clinical benefit rate was 77%, and the 
median PFS was 8.9 months. Adverse events were expected 
and manageable, with good patient compliance and quality 
of life even after long-term treatment.74
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Some clinical trials evaluated the combination of nab-
paclitaxel with other chemotherapy drugs commonly used 
in first-line treatment for metastatic BC (ie, capecitabine 
and gemcitabine). Schwartzberg et al75 analyzed the efficacy 
of weekly nab-paclitaxel at 125 mg/m2 plus capecitabine 
825 mg/m2 twice daily orally for 15 days per cycle in 46 patients 
with metastatic BC. The ORR was 61% (complete response 
[clinical or radiological] 4% and partial response 57%), seven 
patients had a stable disease ($24 weeks), with an overall 
clinical benefit of 76.1%. The median PFS was 10.6 months 
and median OS was 19.9 months. Another open-label Phase II 
study76 evaluated the combination of weekly nab-paclitaxel 
(125 mg/m2) and gemcitabine (1,000 mg/m2) in 50 nonpre-
treated patients. Findings were that 8% and 42% of patients 
showed a complete and partial response, respectively. The 
median duration of the response was 6.9 months, the median 
PFS 7.9 months, and the median OS was not yet reached. 
The treatment was well-tolerated. An unplanned analysis of 
subgroups showed a clinical response in ten out of 13 patients 
(77%), with TNBC vs 16 of other patients (44%).
Even if it is not possible to draw conclusive consideration 
in this small subgroup of patients, these data suggest the 
possibility that TNBC could be particularly responsive to 
nab-paclitaxel-based regimens.
Nab-paclitaxel and bevacizumab in the 
metastatic setting
The combination of nab-paclitaxel and bevacizumab was 
investigated by several authors in the first-line treatment of 
TNBC. In 2010, Lobo et al77 published an open-label Phase 
II study of first-line treatment with weekly nab-paclitaxel 
(150 mg/m2), bevacizumab (10 mg/kg), and gemcitabine 
(1,500 mg/m2) in 30 patients with metastatic HER2-negative 
BC. The median PFS was 10.4 months and ORR was 75.9%, 
including eight complete responses (27.6%). In this trial, 
13 patients (44.8%) had TNBC. The results showed a good 
clinical response in this subgroup, with a complete response 
in five cases (38.4%), a partial response in four cases (30.7%), 
and stable disease in a further two cases (6.9%). Finally, the 
18-month OS rate was 77.2% in the overall population and 
82.5% (95% CI 46.1%–95.3%) in TNBC patients. Eight 
patients (27.6%) experienced a grade 3/4 toxicity. Since first-
line treatment with a triplet chemotherapy was demonstrated 
to be very active, with an acceptable toxicity, the authors 
suggested further evaluation of this combination.
Hamilton et al78 published, in 2013, the results of a mul-
ticenter Phase II study of the combination of nab-paclitaxel 
plus bevacizumab plus carboplatin in first-line treatment for 
TNBC. Patients received weekly nab-paclitaxel (100 mg/m2) 
plus carboplatin (AUC 2) for three times in a cycle of 28 days 
and bevacizumab (10 mg/kg) at days 1 and 15 of the cycle. 
The treatment was continued until disease progression, unac-
ceptable toxicity, or voluntary withdrawal from protocol. The 
primary end points were safety and tolerability; secondary end 
points were PFS, ORR, and clinical benefit. A total 34 patients, 
with median age 50 years (range: 30–76 years) were enrolled; of 
these, 26 (77%) were treated in the adjuvant setting with anthra-
cyclines and taxanes, and 88% had visceral metastases.
Despite the limitation of the low number of patients, this 
study is very interesting because the triple combination was 
able to obtain encouraging results, with a median PFS of 
9.2 months (95% CI 7.8–25.1 months), and a 6-month and 
9-month progression-free rate of 88% and 64% respectively. 
The ORR was 85%, with 17.7% having complete response 
and a very high rate of clinical benefit (94%) (Figure 2). The 
randomized Phase III CALGB 40502 study compared weekly 
nab-paclitaxel 150 mg/m2 or weekly ixabepilone 16 mg/m2 
to weekly paclitaxel 90 mg/m2, all of them for 3 of 4 weeks 
and associated with bevacizumab, as first-line therapy for 
783 patients with advanced BC. The median PFS was 11 
months for paclitaxel, 7.4 months for ixabepilone (P,0.001), 
and 9.3 months for nab-paclitaxel (P=0.054). In an explor-
ative unplanned subgroup analysis of the TNBC population, 
no significant differences between the nab-paclitaxel plus 
bevacizumab and paclitaxel plus bevacizumab groups were 
observed (median PFS 7.4 and 6.5 months, respectively).79 
It seems that the lack of superiority of nab-paclitaxel over 
paclitaxel in the CALGB study could be attributable to a sub-
optimal drug dose and imperfect knowledge of nab-paclitaxel 
pharmacokinetics in association with bevacizumab80 – the 
dose reductions and treatment interruptions were much higher 
Figure 2 Efficacy parameters in patients with triple-negative BC treated with nab-
paclitaxel/bevacizumab/carboplatin.70
Notes: CBR: 95% Ci 80–99. ORR: 95% Ci 69–95.
Abbreviations: BC, breast cancer; CBR, clinical benefit rate; CI, confidence interval; CR, 
complete response; ORR, overall response rate; PR, partial response; SD, stable disease.
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in the nab-paclitaxel plus bevacizumab arm vs conventional 
paclitaxel plus bevacizumab.
The safety profile was very good: neutropenia and 
thrombocytopenia were the most frequent grade 3/4 adverse 
events (53% and 18% respectively). According to the authors, 
first-line treatment with the combination of nab-paclitaxel, 
bevacizumab, and carboplatin seems to be effective and well-
tolerated in patients with metastatic TNBC, with PFS, ORR, 
clinical benefit, and safety comparable with that observed 
with other standard first-line treatments.
Nab-paclitaxel in the neoadjuvant setting
The neoadjuvant setting is very important as stated before, in 
particular, for the still discussed but widely accepted value 
of pCR as a surrogate point for long-term outcome.18–21,81 
In the past few years, many studies with nab-paclitaxel-based 
neoadjuvant regimens have been published.
Nab-paclitaxel and bevacizumab in the 
neoadjuvant setting
The efficacy and safety profile of the combination of nab-
paclitaxel and bevacizumab was evaluated also in neoad-
juvant therapy in the Phase II SWOG S0800 study.82 This 
study enrolled 215 patients with inflammatory BC (IBC) or 
locally advanced BC, comparing bevacizumab (10 mg/kg 
IV every 14 days for 12 weeks) plus weekly nab-paclitaxel 
100 mg/m2 for 12 weeks followed by AC (doxorubicin 
69 mg/m2 IV for six cycles every 14 days and pegfilgrastim 
6 mg subcutaneously) with nab-paclitaxel alone after or 
before AC.82 Based on its several clinical benefits in terms 
of efficacy and safety, the authors used nab-paclitaxel as the 
backbone of the study. The results showed that the combina-
tion of nab-paclitaxel plus AC was able to obtain a pCR rate 
higher than that of other nab-paclitaxel-free regimens (21% 
vs 10%–11%). Nab-paclitaxel plus bevacizumab significantly 
increased the pCR in the intention-to-treat population (36%), 
with the higher rate in hormone-negative patients (pCR 59% 
vs 28% of controls). It is noteworthy that the combination 
nab-paclitaxel and bevacizumab was not associated with 
increased grade 3/4 toxicity.82
Another interesting Phase II study of neoadjuvant 
treatment83 involved 42 patients with TNBCs .2 cm treated 
with nab-paclitaxel at 100 mg/m2 was given on days 1, 8, 
and 15, and carboplatin (AUC =6) day 1, every 4 weeks 
for four cycles, followed by doxorubicin 60 mg/m2 and 
cyclophosphamide 600 mg/m2, “dose-dense” every 14 days. 
Bevacizumab 10 mg/kg was administered every two weeks 
with chemotherapy, and continued postoperatively for a total 
of 1 year. The pCR rate was very high: 53% in breast and 
lymph nodes; the only severe toxicity was Grade 3 (56%) 
and Grade 4 (24%) neutropenia, preventable with granulocyte 
growth factors. These results are very important considering 
the triple-negative setting.
Neoadjuvant nab-paclitaxel with other 
combinations
One recent Phase II study84 in the neoadjuvant setting 
matched 30 patients with weekly nab-paclitaxel (125 mg) 
and 90 patients with conventional paclitaxel, both com-
bined with carboplatin (AUC =2) and trastuzumab, in the 
HER2-positive population. The results were similar for the 
two taxanes with respect to pCR (nab-paclitaxel 26.7% vs 
paclitaxel 25.6%, and 43.6% vs 39.6% with trastuzumab, 
respectively). Grade 4 neutropenia was higher with nab-
paclitaxel. This study is small, as stated by the authors, 
with just two TNBC cases, but it confirms the study by 
Snider et al83 regarding the need of growth factors use 
when combining a taxane with carboplatin. The strength 
of this combination is the absence of anthracycline, which 
is interesting for cardiopathic patients. The authors cited, 
in the concluding remarks, several “ongoing large Phase 
III trials able to provide a definitive answer on the role of 
nab-paclitaxel in the neoadjuvant setting”. We believe this 
recently happened with the reporting of the GeparSepto85 
trial, in which there were 275 TNBCs.
The GeparSepto study
The GeparSepto (NCT01583426)85 neoadjuvant study 
compared weekly nab-paclitaxel (at the initial dose of 
150 mg/m2/week in the first 400 patients, amended for tox-
icity to 125 mg/m2/week in the next 800), or conventional 
paclitaxel (80 mg/m2/week) for 12 weeks, both followed by 
four cycles of epirubicin plus cyclophosphamide, in more 
than 1,200 patients with early BC (275 with TNBC). The 
results were presented at the 2014 San Antonio Breast Can-
cer Symposium. In this study, HER2-positive patients with 
a planned treatment with pertuzumab (loading dose 840 mg 
followed by 420 mg every 4 weeks) and trastuzumab (load-
ing dose 8 mg/kg, followed by 6 mg/kg every 4 weeks) were 
also included. The primary end point was pCR (defined as 
ypT0 ypN0 or N-positive); the secondary end points were 
pCR defined as ypT0/is ypN0 and ypT0 ypN0 0/+, toxicity, 
compliance, and pCR associated to secreted protein acidic 
and rich in cysteine (SPARC) expression. Some subgroup 
analyses were preplanned as per protocol. A total 23% of 
patients in both arms had a TNBC. The pCR rate (ypT0 
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ypN0) was 29% in patients treated with paclitaxel and 38% 
in patients treated with nab-paclitaxel (OR 1.5, P,0.01) 
(Figure 3).
The primary end point of pCR was reached with statistical 
significance. Actually, the odds ratio was 1.53, indicating a 
53% higher likelihood of achieving a pCR with albumin-
bound paclitaxel than with conventional paclitaxel.
The benefit observed with nab-paclitaxel was confirmed 
in all the subgroups of patients; in particular, it is noteworthy 
that in the TNBC population, the pCR was almost doubled 
(48.2% vs 25.7%) (P,0.001). Globally, due to this very 
high increase of response in TNBC, nab-paclitaxel can be 
considered a valid therapeutic approach for the management 
of a disease characterized by a very poor prognosis.
Safety profile
Other important information from this study is the planned 
schedule, ie, weekly nab-paclitaxel 150 mg/m2, already 
used by Gradishar et al.69 After the enrolment of the first 
400 patients, the protocol was amended, reducing the dose 
of weekly nab-paclitaxel to 125 mg/m2 for the further 800 
patients. The safety profile was correctly reported (intent-to-
treat) for all the study population, showing the higher efficacy 
but also the higher toxicity of nab-paclitaxel in terms of grade 
3/4 sensitive neuropathy (10.2% vs 2.7%). However, when 
considering (“per treatment given”) only the patients treated 
with the dose of 125 mg/m2 of nab-paclitaxel (800/1,200), 
the efficacy is the same but the toxicity is lower, without 
any difference in Grade 3 and Grade 4 toxicity (5.3% vs 
5.7%) (Table 3).
An issue in the comparison between nab-paclitaxel and 
conventional paclitaxel in terms of neurotoxicity was also 
recently discussed at the ASCO 2015 meeting. In a Phase II 
trial (NCT0163710) of first-line treatment of metastatic HER2-
negative BC by Ciruelos et al86 weekly conventional paclitaxel 
(80 mg/m2) was compared with weekly nab-paclitaxel at the 
dose of 100 mgs/sqm days 1, 8, 15; 150 mgs/sqm days 1, 8, 
15 or 150 mgs/sqm days 1, 15; any dose level any 28 days; 
neuropathy was the primary end point and neutropenia one of 
the secondary end points. The authors reported, as expected, 
an increased rate of Grade 3 neutropenia with weekly nab-
paclitaxel at 150 mg, but no difference was reported between 
arms in terms of neurotoxicity or overall neutropenia.
Another trial – the randomized Phase II “ADAPT TN” 
trial – was reported at the ASCO 2015 meeting by Gluz 
et al.87 Gemcitabine and carboplatin are interesting partners 
for taxane combinations, and the trial randomized 336 
TNBC patients to 12 weeks of neoadjuvant nab-paclitaxel 
(125 mgs/sqm) and gemcitabine (1000 mgs/sqm) days 1 and 
8 q3w or carboplatin (AUC =2). The end point was to identify 
early response markers for pCR (ypT0 ypN0) (drop of Ki-67 
after 3 weeks from treatment start). The preplanned interim 
analysis with the first 130 patients was presented. pCR was 
reported in 25% of patients treated with nab-paclitaxel plus 
gemcitabine and in 49.2% of cases with nab-paclitaxel plus 
carboplatin (P=0.006).
One more interesting paper on nab-paclitaxel was pre-
sented at the ASCO 2015 meeting, by Matsuda et al from the 
MD Anderson Cancer Center,88 based on the observations that 
EGFR overexpression is an independent poor prognostic fac-
tor in IBC and that in animal models an anti-EGFR treatment 
was able to inhibit IBC growth. In this single-arm Phase II 
study, 25 IBC patients were treated with the anti-EGFR 
Figure 3 Pathological Response rate in patients treated with conventional paclitaxel or nab-paclitaxel.84 
Notes: ypT0ypN0: absence of tumor cells in Tumor and Nodes. ypT0/ispN0: absence of tumor cells in Tumor and Nodes, but in situ cancer cells in the tumor allowed. ypT0/
isypN0/+: Absence of tumor cells in Tumor and Nodes, but positive Nodes also allowed.
Abbreviation: pCR, pathological complete response.
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Table 3 Sensorial neuropathy (nab-paclitaxel at 125 mg/m2)84
Paclitaxel % Nab-paclitaxel % P-value
No neuropathy 57.9 37.7 0.038
Any G toxicity 42.1 62.3 ns
G3/4 5.3 5.7 ns
Abbreviations: G, grade; ns, not significant.
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monoclonal antibody panitumumab (2.5 mg/kg), nab-
paclitaxel (100 mg/m2), and carboplatin (AUC =2) weekly, 
for four cycles, followed by four cycles of 5-Fluoruracile, 
Epirubicine at 100 mg/sqm, Cyclophosphamide regimen, 
surgery, radiation, and endocrine adjuvant treatment in ER-
positive cases. The overall pCR rate (primary end point) 
was 36% and was 60% in TNBC and 20% in ER-positive 
patients. The association of pCR with subtype showed just a 
trend to significance, essentially due to the small sample size. 
This excellent result was not “for free” because Grade 3 and 
4 hematological events occurred in 72% and other Grade 3 
events in a further 36% though the median age of patients was 
57 years and patients were fit. The historical pCR rate in IBC 
is around 15% and the prognosis poor. These data have no 
precedent, and a randomized Phase III trial is now starting.
Two clinical case reports
Case report 1
A 52-year-old woman with primary TNBC metastasized to 
bones, locoregional and mediastinal nodes, and lung, was 
treated with nab-paclitaxel, gemcitabine, and bevacizumab. Pain 
improved within a few weeks, (complete withdrawal of analgesic 
therapy). After 7 months, a complete radiological response was 
observed and maintained for 2 years, with a dose reduction due to 
asthenia but without other adverse events. The patient maintained 
normal daily activities, including work; the disease progression 
occurred after 24 months. Subsequent treatments stabilized the 
disease; however, death occurred after another 2 years. This 
case is indicative of how a treatment with nab-paclitaxel, beva-
cizumab, and gemcitabine can be very effective with minimal 
toxicity in selected patients with metastatic TNBC.89
Case report 2
A 51-year-old women with TNBC, BRCA1-mutated, was 
treated with four cycles of a neoadjuvant carboplatin and etopo-
side regimen with a complete clinical/radiological response. 
A local progression after 19 months was treated with dose-
dense AC with growth factor support, followed by paclitaxel 
q3w for four cycles, with an optimal disease control. After 
a further 3 years, diffuse brain metastases were discovered, 
treated with whole-brain radiation, in a rapidly progressive 
disease (with massive liver and retroperitoneal nodes, and mul-
tiple, bilateral pulmonary involvement). The patient started a 
carboplatin (AUC =5) plus weekly nab-paclitaxel 100 mg/m2 
regimen. Despite growth factor support, carboplatin was 
suspended after four cycles, and nab-paclitaxel monotherapy, 
at 90 mg/m2 weekly for 3 out 4 weeks, was continued. After 
4 months, a partial response with clinical improvement 
was observed and maintained for another 4 months until 
asymptomatic cerebral disease progression, followed by 
a rapid deterioration in the patient’s condition and exitus 
after 2 months.
This case is very interesting because it shows that in a patient 
heavily treated with carboplatin, etoposide, conventional pacli-
taxel, and anthracycline, third-line nab-paclitaxel, first combined 
with carboplatin for four cycles and then as monotherapy, was 
able to obtain a partial clinical/radiological response lasting 
for 8 months, with concomitant resolution of symptoms (pain, 
dyspnea, and severe asthenia) and virtual lack of toxicity.90
New clinical trials of nab-paclitaxel 
in TNBC
Some interesting trials with nab-paclitaxel in TNBC are 
currently ongoing.
Tn Acity (ClinicalTrials.gov identifier 
NCT01881230)91
•	 Randomized Phase II/III study of weekly nab-paclitaxel 
associated to gemcitabine or carboplatin vs gemcitabine 
plus carboplatin, in the first-line treatment of TNBC
•	 Phase II end points: efficacy (PFS) and safety of nab-
paclitaxel 125 mg/m2 associated to gemcitabine or 
carboplatin vs their combination (randomized 1:1:1) 
(n=240) – in order to identify the best nab-paclitaxel-
based regimen to compare in the Phase III with the stan-
dard regimen, gemcitabine plus carboplatin (randomized 
1:1) (n=550)
•	 Phase III end point: PFS
•	 Phase III stratification factors: DFS , or .12 months, 
pretreatment with taxanes in the adjuvant or neoadjuvant 
setting
•	 In both the study phases, treatment will continue until 
disease progression or unacceptable toxicity.
As of May 31, 2015, 176 patients were enrolled in the 
Phase II trial.
eTNA (ClinicalTrials.gov identifier 
NCT01822314)
•	 Randomized Phase III study on neoadjuvant therapy with 
weekly nab-paclitaxel
•	 632 patients with early HER2-negative BC at high risk of 
relapse, Eastern Cooperative Oncology Group (ECOG) 
performance status 0–1, to be randomized to weekly 
nab-paclitaxel 125 mg/m2 (three doses per cycle) for four 
cycles vs conventional weekly paclitaxel 90 mg/m2 (three 
doses per cycle) for four cycles, followed by four cycles 
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of anthracycline-based regimens, surgery, and a 10-year 
follow up
•	 Primary end point: pCR (ypT0/ypTis, ypN0)
•	 Secondary end points:
	 pCR in endocrine receptor-positive vs triple-negative 
tumors
	 ORR after four cycles of both taxanes and before 
surgery
	 EFS (local, regional, and distant) and OS
	 Safety and tolerability; clinical and molecular 
tests able to identify markers predictive of clinical 
benefit.
Conclusion
TNBC is characterized by the absence of ER-, PgR-, and 
HER2-negativity: for this reason the only therapeutic option 
is chemotherapy. Even if these tumors are chemosensitive, as 
showed by the high pCR obtained with neoadjuvant therapy, 
metastatic patients have a short PFS; thus the chemosensitiv-
ity does not translate in an improvement of PFS or OS, and 
the overall prognosis for these tumors is poor.
The studies performed with taxane-based chemotherapy 
demonstrated their efficacy in the treatment of TNBC in any 
setting (neoadjuvant, adjuvant, and metastatic): international 
and national guidelines recommend the taxanes as possible 
active first-line therapeutic options for TNBC.
Nab-paclitaxel, a nanoparticle of albumin-bound pacli-
taxel, allows achievement of higher intratumoral concentra-
tions of active drug and is demonstrated to be more effective 
and less toxic that conventional taxanes in metastatic BC; 
even in the case of aggressive and visceral disease and in 
neoadjuvant setting, the pCR is superior vs conventional 
taxanes.
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